The results with agonists demonstrate apelin is limited to two principal actions in humans in health and disease: modest vasodilatation within the first hour of systemic infusion and a beneficial increase in cardiac output that is maintained for up to six hours in patients with heart failure (Barnes et al., 2013). The gene discussed is APLN; the disease is heart failure.